SEC Comment Letter 0000000000-23-010855 to Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc.
Date: Sept. 29, 2023 · CIK: 0001636282 · Accession: 0000000000-23-010855
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273769
Referenced dates: August 28, 2023
Letter
United States securities and exchange commission logo September 29, 2023 Jonathan D. Alspaugh President and Chief Financial Officer Aeglea BioTherapeutics, Inc. 221 Crescent Street Building 17, Suite 102B Waltham, MA 02453 Re:Aeglea BioTherapeutics, Inc. Registration Statement on Form S-3 Response dated September 8, 2023 File No. 333-273769 Dear Jonathan D. Alspaugh: We have limited our review of your registration statement to those issues we have addressed in our comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Registration Statement on Form S-3 General 1.We note your response to comment 1 from our letter dated August 28, 2023. Based on the totality of the transactions, including the entry into the CVR agreement and disposition of the legacy assets, as well as the termination of the legacy employees and executives, we are unable to concur with your analysis. Please amend your registration statement to register the offering on Form S-1.
FirstName LastNameJonathan D. Alspaugh Comapany NameAeglea BioTherapeutics, Inc. September 29, 2023 Page 2 FirstName LastName Jonathan D. Alspaugh Aeglea BioTherapeutics, Inc. September 29, 2023 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Dillon Hagius at 202-551-7967 or Joe McCann at 202-551-6262 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Branden C. Berns
Show Raw Text
United States securities and exchange commission logo
September 29, 2023
Jonathan D. Alspaugh
President and Chief Financial Officer
Aeglea BioTherapeutics, Inc.
221 Crescent Street
Building 17, Suite 102B
Waltham, MA 02453
Re:Aeglea BioTherapeutics, Inc.
Registration Statement on Form S-3
Response dated September 8, 2023
File No. 333-273769
Dear Jonathan D. Alspaugh:
We have limited our review of your registration statement to those issues we have
addressed in our comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to this comment, we may have additional comments.
Registration Statement on Form S-3
General
1.We note your response to comment 1 from our letter dated August 28, 2023. Based on the
totality of the transactions, including the entry into the CVR agreement and disposition of
the legacy assets, as well as the termination of the legacy employees and executives, we
are unable to concur with your analysis. Please amend your registration statement to
register the offering on Form S-1.
FirstName LastNameJonathan D. Alspaugh
Comapany NameAeglea BioTherapeutics, Inc.
September 29, 2023 Page 2
FirstName LastName
Jonathan D. Alspaugh
Aeglea BioTherapeutics, Inc.
September 29, 2023
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Dillon Hagius at 202-551-7967 or Joe McCann at 202-551-6262 with any
other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Branden C. Berns